Lijuan Chen
China National Nuclear Corporation(CN)Chengdu Medical College(CN)University of Jinan(CN)Guangzhou University(CN)Zhengzhou University(CN)Huaian First People’s Hospital(CN)People's Liberation Army 401 Hospital(CN)Henan Provincial People's Hospital(CN)Jiangsu Province Hospital(CN)Jingning County People's Hospital(CN)Nanjing Medical University(CN)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research, Peptidase Inhibition and Analysis, Advanced biosensing and bioanalysis techniques
Most-Cited Works
- → Presumed Asymptomatic Carrier Transmission of COVID-19(2020)4,840 cited
- → Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma(2019)400 cited
- → First-principles calculations of equilibrium Mg isotope fractionations between garnet, clinopyroxene, orthopyroxene, and olivine: Implications for Mg isotope thermometry(2013)154 cited
- → COVID-19 Disease With Positive Fecal and Negative Pharyngeal and Sputum Viral Tests(2020)150 cited
- → An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma(2008)139 cited
- → Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)(2022)